Company: IMNN
Filing Date: 2025-05-13
Form Type: S-1/A
Source: 0001641172-25-009814
Chunk: 40

Company: Imunon, Inc.
Filing Date: 2025-05-13
Form: S-1/A
Chunk 40
---
 regulations of Nasdaq from the stockholders of the Company and board of directors of the Company: (a) to consent to any adjustment to the exercise price and/or number of shares of Common Stock underlying the common warrants in the event of an adjustment upon the Adjustment Date (as defined below) pursuant to the terms of the common warrants, (b) to consent to any adjustment to the exercise price of the common warrants in the event of a voluntary adjustment pursuant to the terms of the common warrants, and (c) to consent to the “alternative cashless exercise” provision of the common warrants, in each case without regard to any limitations upon exercise of the common warrants relating to Stockholder Approval (as defined below) and/or the provisions prohibiting adjustments in such common warrants above the price set forth in clause (ii) of the definition of Floor Price (as defined below); and (ii) such approval as may be required from the stockholders of the Company and board of directors of the Company as necessary to increase the available number of authorized shares of Common Stock of the Company to a minimum of [●] million authorized shares. We have agreed to hold a meeting to obtain Stockholder Approval as soon as practicable following the closing of this offering, but no later than sixty (60) days following the closing of this offering, and further agreed to cause an additional stockholder meeting to be held every ninety (90) days thereafter until such Stockholder Approval is obtained. We cannot assure you that we will be able to obtain requisite Stockholder Approval. In the event that we are unable to obtain Stockholder Approval, the common warrants will not be exercisable and therefore will have no value.

Fundamental Transaction

In the event of a fundamental transaction, as described in the common warrants and generally including merger or consolidation of the Company or the sale of all or substantially all of the Company’s capital stock or assets, the holders of the common warrants will be entitled to receive upon exercise of the common warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the common warrants immediately prior to such fundamental transaction. Notwithstanding the foregoing, in the event of a fundamental transaction, the holders of common warrants have the right to require the Company or a successor entity to purchase the common warrants from the holder for an amount of consideration equal to the Black Scholes Value (as defined in the common warrants) of the remaining unexercised portion of the common warrants concurrently with or within 30 days following the consummation of a fundamental